Every 10-Q that Cognex Corp (CGNX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CGNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGNX filings page.
Cognex delivered significantly stronger results in Q2 2026, with revenue of $291,263,000, up 17% year over year, and gross margin improving to 71% from 67%. Operating income rose to $85,517,000 (29% of revenue), and net income reached $72,756,000, or $0.43 per diluted share.
For the first half of 2026, revenue grew 20% to $559,700,000 and net income was $124,460,000, supported by broad-based demand, especially in Greater China and the Americas, while Europe was softer. Cognex held $755,013,000 in cash and investments with no long‑term debt, generated $114,246,000 of operating cash flow, repurchased 2,501,000 shares for $105,231,000, and paid dividends totaling $28,454,000 in six months.
Cognex Corporation delivered a much stronger first quarter of 2026, with revenue of $268.4 million, up 24% from a year earlier. Growth was broad-based across Americas, Europe, Greater China, and other Asia, helped by consumer electronics, semiconductor, logistics, and packaging demand.
Gross margin improved to 71% from 67%, lifting operating income to $59.9 million, or 22% of revenue. Net income more than doubled to $51.7 million, or $0.31 per diluted share. Cognex generated $45.1 million of operating cash flow, repurchased $99.0 million of stock, completed a small Japan business divestiture, and ended the quarter with $621.9 million in cash and investments and no long‑term debt.
Cognex Corporation reported stronger operations in Q3 2025, with revenue of $276,892,000, up 18% year over year, and gross margin steady at 68%. Operating income rose to $57,765,000 (21% of revenue) as expenses were essentially flat, reflecting cost controls and higher incentive accruals tied to performance.
Net income fell to $17,664,000, or $0.10 per diluted share, primarily due to a discrete tax expense of approximately $33,265,000 from newly enacted U.S. tax legislation (OBBBA), which lifted the effective tax rate to 72%. Excluding discrete items, the company cited an effective tax rate of 18% for the quarter.
Geographically, revenue grew in the Americas (+27%) and Europe (+30%), with Greater China up 10% and Other Asia down 4%. Results included about $13 million of one-time license and inventory transfer revenue from a new medical lab automation partnership. Year to date, operating cash flow was $170,612,000; cash and investments totaled $600,344,000. The company repurchased 3,594,000 shares for $126,233,000, leaving $140,020,000 authorized, and declared a subsequent dividend of $0.085 per share.